SRR934924
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7.851511169513797
- age_years
- 49
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.646
- INTERFERON_GAMMA_RESPONSE+0.615
- INFLAMMATORY_RESPONSE+0.570
- IL6_JAK_STAT3_SIGNALING+0.539
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.538
- ALLOGRAFT_REJECTION+0.517
- PROTEIN_SECRETION+0.508
- COMPLEMENT+0.500
- TNFA_SIGNALING_VIA_NFKB+0.459
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.458
Top 10 suppressed
- KRAS_SIGNALING_DN-0.311
- PANCREAS_BETA_CELLS-0.290
- SPERMATOGENESIS-0.290
- MYC_TARGETS_V2-0.274
- WNT_BETA_CATENIN_SIGNALING-0.245
- DNA_REPAIR-0.164
- E2F_TARGETS-0.147
- HEDGEHOG_SIGNALING-0.141
- NOTCH_SIGNALING-0.092
- G2M_CHECKPOINT-0.063
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934945 | — | — | 0.973 |
| 2 | SJEPD031078_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.943 |
| 3 | SRR934811 | — | — | 0.937 |
| 4 | SRR934884 | — | — | 0.932 |
| 5 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.932 |
| 6 | SRR934729 | — | — | 0.930 |
| 7 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.920 |
| 8 | SRR12696731 | — | — | 0.918 |
| 9 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.916 |
| 10 | SRR934901 | — | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.646 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.615 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.539 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.538 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.517 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.508 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.459 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.458 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.437 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.427 | Idelalisib | — uncovered |
| APOPTOSIS | 0.420 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.416 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.373 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.353 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.318 | Inavolisib | — uncovered |
| COAGULATION | 0.312 | Binimetinib | — uncovered |
| HYPOXIA | 0.283 | Idelalisib | — uncovered |